Page 31 - Read Online

Cidon. J Unexplored Med Data 2018;3:8 I http://dx.doi.org/10.20517/2572-8180.2018.03 Page 15 of 16

induced regulatory T cells. J Exp Med 2009;206:3015-29.
24. National Comprehensive Cancer Network. Colon cancer (Version 2.2017). Available from: https://www.nccn.org/professionals/physician_
gls/pdf/colon.pdf. [Last accessed on 27 Sep 2018]
25. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med
2015;372:2509-20.
26. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1
monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015;21:4286-93.
27. Diaz LA, Marabelle A, Delord J, Shapira-Frommer R, Geva R, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H)
colorectal cancer (CRC) and non-CRC. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3071#affiliationsCon
tainer. [Last accessed on 27 Sep 2018]
28. Overman M, Kopetz S, McDermott R, Leach J, Lonardi S, et al. Nivolumab ± ipilimumab in treatment of patients with metastatic
colorectal cancer with and without high microsatellite instability: CheckMate 142 interim results. Available from: https://www.
primeoncology.org/app/uploads/prime_activities/25105/overman.pdf. [Last accessed on 27 Sep 2018]
29. Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, et al. Nivolumab in patients with DNA mismatch repair deficient/
microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. Availabe from: http://ascopubs.org/doi/
abs/10.1200/JCO.2017.35.4_suppl.519. [Last accessed on 27 Sep 2018]
30. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in
refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
31. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in
cancer. N Engl J Med 2012;366:2443-54.
32. Diaz LA, Le DT, Yoshino T, Andre T, Bendell JC, et al. KEYNOTE-177: randomized phase III study of pembrolizumab versus
investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.
Available from: http://ascopubs.org/doi/10.1200/JCO.2017.35.4_suppl.TPS815. [Last accessed on 27 Sep 2018]
33. Emambux S, Tachon G, Junca A, Tougeron D. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opin
Biol Ther 2018; doi: 10.1080/14712598.2018.1445222.
34. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced
cancer. N Engl J Med 2012;366:2455-65.
35. Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent
airway hyperreactivity in opposing directions. Mucosal Immunol 2010;3:81-91.
36. Sinicrope FA, Ou FS, Shi Q, Nixon AB, Mody K, et al. Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant
therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance
A021502). Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS3630. [Last accessed on 27 Sep 2018]
37. Bendell JC, Powderly JD, Lieu CH, Eckhardt SG, Hurwitz H, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination
with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). Available from: http://ascopubs.org/
doi/10.1200/jco.2015.33.3_suppl.704. [Last accessed on 27 Sep 2018]
38. Hochster HS, Bendell JC, Cleary JM, Foster P, Zhang W, et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev)
in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). J Clin Oncol 2017; doi: 10.1200/
JCO.2017.35.4_suppl.673.
39. Bendell JC, Kim TW, Goh BC, Wallin J, Oh DY, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal
cancer (CRC). Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3502. [Last accessed on 27 Sep 2018]
40. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in
colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51.
41. Beatty GL, O’Dwyer PJ, Clark J, Shi JG, Bowman KJ, et al. First-in-human phase 1 study of the oral inhibitor of indoleamine
2,3-dioxygenase-1epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res 2017;23:3269-76.
42. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and
improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014;74:5057-69.
43. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, et al. Cetuximab-activated natural killer and dendritic cells collaborate to
trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013;19:1858-72.
44. Eynde MVD, Mlecnik B, Machiels JPH, Debetancourt D, Bindea G, et al. Characterization of the immune microenvironment of
synchronous primary tumor and liver colorectal metastases. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_
suppl.3610. [Last accessed on 27 Sep 2018]
45. Lee SJ, Kim JG, Chae YS, Kang BW, Lee IH, et al. Association of LAG-3 expression in tumor infiltrating immune cells with prognosis
in patients with microsatellite instability high colon cancer. Availale from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.
e15126. [Last accessed on 27 Sep 2018]
46. Zhou G, Noordam L, Sprengers D, Doukas M, Boor PPC, et al. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in
mismatch repair-proficient liver metastases of colorectal cancer. Oncoimmunology 2018;7:e1448332.
47. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011;239:27-44.
48. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, et al. Active specific immunotherapy for stage II and stage III human
colon cancer: a randomised trial. Lancet 1999;353:345-50.
49. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, et al. Immunotherapy with autologous tumor cell-BCG vaccine
in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005;23:2379-87.
50. Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, et al. Active specific immunotherapy with newcastle-disease-virus-
modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a